ZOVIRAX SUSPENSION
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
31-05-2016
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
ACYCLOVIR
제공처:
GLAXOSMITHKLINE INC
ATC 코드:
J05AB01
INN (International Name):
ACYCLOVIR
복용량:
200MG
약제 형태:
SUSPENSION
구성:
ACYCLOVIR 200MG
관리 경로:
ORAL
패키지 단위:
125ML
처방전 유형:
Prescription
치료 영역:
NUCLEOSIDES AND NUCLEOTIDES
제품 요약:
Active ingredient group (AIG) number: 0115506003; AHFS:
승인 상태:
APPROVED
승인 날짜:
2001-08-07
제품 특성 요약
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
ZOVIRAX
®
Acyclovir Oral Suspension USP, 200 mg /5 mL
Antiviral Agent
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
May 30, 2016
Submission Control No: 191703
_©_
_2016 GlaxoSmithKline Inc. All Rights Reserved _
_ZOVIRAX is a registered trademark of GlaxoSmithKline Inc. _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICAL TRIALS
..........................................................................................................15
DETALIL
전체 문서 읽기
